$MRK Merck & Co Q3 Earnings
Adj. EPS $2.49, est. $2.07 Rev. $18.09B, est. $17.31B Keytruda rev. $8.60B, est. $8.38B Gardasil rev. $2.00B, est. $1.75B Keytruda Qlex rev. $830M, est. $699.6M Winrevair rev. $694M, est. $643.1M Animal Health sales $1.68B, est. $1.69B Sees FY sales $66.8B to $67.3B, saw $66.3B to $67.3B Sees FY Adj. EPS $2.77 to $2.82, saw $2.66 to $2.76 Still sees FY Adj. gross margin about 81%, est. 81%
Adj. EPS $2.49, est. $2.07 Rev. $18.09B, est.
$17.31B Keytruda rev. $8.60B, est. $8.38B Gardasil rev. $2.00B, est.
$1.75B Keytruda Qlex rev. $830M, est. $699.6M Winrevair rev. $694M, est.
$643.1M Animal Health sales $1.68B, est. $1.69B Sees FY sales $66.8B to $67.3B, saw $66.3B to $67.3B Sees FY Adj. EPS $2.77 to $2.82, saw $2.66 to $2.76 Still sees FY Adj. gross margin about 81%, est.
81%